Portfolio
AndzonBio1 is developing a pipeline of First-In-Class therapeutics aiming to enter IND-enabling studies by 2028
Programs
Drug discovery
Lead
IND/CTA
01Liver Fibrosis
Small Molecule Entity (SME)
02Cardiac Fibrosis
Antibody
03Under evaluation
04Under evaluation
Cardiovascular
Metabolic
Renal
Contact
10, rue d’Oradour-sur-Glane
75015 Paris
Contact us for any questions:
contact@andzonbio1.com